hoot there it is

Rice rises to top of new ranking of Texas colleges and universities

The Owls have soared to the top again. Photo courtesy of Rice University

If Texas had one Ivy League school, it would have to be Rice University.

Time after time, the Houston school ranks as the best college or university in Texas and one of the best in the country. Personal finance website WalletHub just added to Rice's accolades with a No. 1 ranking in Texas and a No. 6 ranking nationally among colleges and universities.

In Texas, Rice appears at No. 1 for admission rate, graduation rate, gender and racial diversity, and post-school median salary. Not every ranking is that stellar, though. Rice ranks 50th for on-campus crime among 55 Texas schools and 52nd for net cost.

More students soon will be able to take advantage of Rice's top-tier education. In March, the school said it would enlarge its undergraduate enrollment by 20 percent — to 4,800 — by the fall of 2025, up from more than 4,200 in the fall of 2020.

In a news release, Robert Ladd, chairman of the Rice Board of Trustees, called expansion of the student body "a strategic imperative."

"Expanding the student body now will also expand Rice's future alumni base across the nation and around the world," he added. "Welcoming more students to the Rice campus today will have an impact on the university for generations to come."

Elsewhere on the WalletHub list, the University of Houston lands at No. 10 within Texas and No. 238 in the country.

To determine the top-performing schools, WalletHub compared more than 1,000 institutions in the U.S. across 30 key measures, including student-to-faculty ratio, graduation rate, and post-school median salary.

Here are the top 15 colleges and universities in Texas, according to WalletHub, along with their national rankings:

  1. Rice University, No. 6 nationally.
  2. University of Texas at Austin, No. 45 nationally.
  3. Trinity University in San Antonio, No. 61 nationally.
  4. Texas A&M University in College Station, No. 127 nationally.
  5. Southwestern University in Georgetown, No. 144 nationally.
  6. University of Dallas, No. 152 nationally.
  7. Southern Methodist University in University Park, No. 178 nationally.
  8. Austin College in Sherman, No. 192 nationally.
  9. LeTourneau University in Longview, No. 231 nationally.
  10. University of Houston, No. 238 nationally.
  11. University of Texas at Dallas, No. 252 nationally.
  12. Texas Christian University in Fort Worth, No. 253 nationally.
  13. Baylor University in Waco, No. 357 nationally.
  14. Texas Lutheran University in Seguin, No. 375 nationally.
  15. Southwest Adventist University in Keene, No. 407 nationally.
------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted